Benefits of sphingosine-1-phosphate receptor modulators in relapsing MS estimated with a treatment sequence model
Previous
Previous
Cost–effectiveness of alternative NTRK testing strategies in cancer patients followed by histology-independent therapy with entrectinib: an analysis of three European countries
Next
Next